Skip to main content
Figure 5 | BMC Cancer

Figure 5

From: γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments

Figure 5

Cellular biomarker responses in HT29 cells exposed to various cytotoxic chemotherapeutic agents in combination with the Chk1 inhibitor V158411. HT29 cells were exposed to the combination GI80 of gemcitabine (0.2 μM), camptothecin (0.44 μM), cisplatin (68 μM), oxaliplatin (131 μM), doxorubicin (1.2 μM) or etoposide (59 μM) for 18 hours followed by DMSO (−) or 400 nM V158411 (+) for a further 24 hours. Protein expression was characterized by immunoblotting.

Back to article page